Light trails left by vehicle headlights on a bridge road at night and illuminated skyscraper skyline
US

Amarin Cuts Risk of Death by 32% in Cancer Trial

In Amarin's Phase 3 EMT2 trial, Vascepa reduced the risk of death by 32%, raising 5-year survival to 62% in colorectal cancer that spread to the liver.
Yatırım Masası2 min read

A 32% reduction in the 5-year risk of death highlighted Phase 3 trial results for Amarin Corporation plc (NASDAQ: AMRN) and its drug VAZKEPA/VASCEPA (icosapent ethyl). Data from the Phase 3 EMT2 study, sponsored by the University of Leeds and funded by Yorkshire Cancer Research, were presented on October 25, 2026, at the European Society for Medical Oncology (ESMO) 2026 Congress held in Madrid, Spain.

What results were obtained in Amarin's Phase 3 cancer study?

Prescription icosapent ethyl, administered in addition to standard care in colorectal cancer liver metastases (CRCLM) patients undergoing liver resection, was tested using the clinical formulation and dosage from the REDUCE-IT cardiovascular outcomes trial. The study did not meet its primary endpoint of progression-free survival (PFS). In the intent-to-treat (ITT) patient population, median PFS was recorded at 13.5 months in the icosapent ethyl arm and 12.9 months in the placebo arm (adjusted hazard ratio 0.89; 95% CI 0.70 to 1.13; p=0.329).

How much did Vascepa increase the overall survival rate?

Despite missing the target on disease progression time, a statistically significant advantage was achieved in the study's key secondary endpoint of overall survival (OS). Compared with 45.1% in the placebo group, the 5-year overall survival estimate reached 62.0% in the group receiving icosapent ethyl. The resulting data indicated an approximately 32% decline in the risk of death compared to the control group (adjusted hazard ratio 0.68; 95% CI 0.48 to 0.96; p=0.030).

In the study, icosapent ethyl was found to be safe, with no excess in adverse events such as bleeding episodes, atrial fibrillation, or deterioration in quality of life reported. The study's lead investigator, Professor Mark Hull, stated that observing an overall survival benefit without a difference in progression-free survival is a recognized phenomenon in oncology trials, noting that potential mechanisms including the drug's direct anti-inflammatory or anti-neoplastic activities and its effects on gut microbiota will be explored in further analyses. Steve Ketchum, Amarin's Head of R&D, also emphasized the significance of this survival benefit provided on top of existing surgical and standard of care treatments.

This content is for information purposes only and does not constitute investment advice.

Add Yatırım Masası as a preferred source on Google
This article is a translation of the original Turkish version published by Yatırım Masası. Read the original in Turkish
Prepared by the Yatırım Masası newsroom from current market developments and official data.
This is not investment advice. The data and commentary in this article are for information only; make investment decisions based on your own research and, where needed, advice from a licensed professional.

Latest news